| Bladder Cancer |
0 |
0.92 |
| Cancer |
0 |
0.9 |
| Biologic Therapy |
0 |
0.84 |
| Renal Cell Carcinoma |
0 |
0.82 |
| Prostate Cancer |
0 |
0.71 |
| Squamous Cell Carcinoma |
0 |
0.67 |
| Adrenocortical Carcinoma |
0 |
0.63 |
| Palliative Care |
0 |
0.62 |
| Tumor |
0 |
0.59 |
| Toxicology |
0 |
0.53 |
| Targeted Cancer Therapy |
0 |
0.52 |
| Genomic Medicine |
0 |
0.51 |
| Advanced Cancer |
0 |
0.5 |
| Kidney Cancer |
0 |
0.5 |
| Penile Cancer |
0 |
0.48 |
| Adrenal Tumor |
0 |
0.45 |
| Germ Cell Tumor |
0 |
0.44 |
| Bladder |
0 |
0.22 |
| Immunotherapy |
0 |
0.16 |
| Clinical Research |
0 |
0.14 |
| Squamous Cell Carcinoma of Penis |
0 |
0.14 |
| Penis |
0 |
0.11 |
| Histology |
0 |
0.1 |
| Surgery |
0 |
0.06 |
| Adenocarcinoma |
0 |
0.05 |
| Chemotherapy |
0 |
0.05 |
| Microsatellite Instability |
0 |
0.05 |
| Prostate Adenocarcinoma |
0 |
0.05 |
| Referral |
0 |
0.05 |
| Aminotransferase |
0 |
0.03 |
| Europe |
0 |
0.03 |
| Food and Drug Administration (FDA) |
0 |
0.03 |
| Neoadjuvant Therapy |
0 |
0.03 |
| Prostate |
0 |
0.03 |
| Board Certification |
0 |
0.02 |
| California |
0 |
0.02 |
| Clinical Guidelines |
0 |
0.02 |
| Diarrhea |
0 |
0.02 |
| Face |
0 |
0.02 |
| Fatigue |
0 |
0.02 |
| Geriatrics |
0 |
0.02 |
| Health Education and Counseling |
0 |
0.02 |
| Hypophosphatemia |
0 |
0.02 |
| Kidney |
0 |
0.02 |
| Medical Oncology |
0 |
0.02 |
| Multiple Sclerosis |
0 |
0.02 |
| Ohio |
0 |
0.02 |
| Pelvis |
0 |
0.02 |
| Rare Diseases |
0 |
0.02 |
| Refractory |
0 |
0.02 |
| Steroids |
0 |
0.02 |
| Testes |
0 |
0.02 |
| Texas |
0 |
0.02 |
| Travel Medicine |
0 |
0.02 |